4.5 Article Proceedings Paper

In vitro screening of the open source Pathogen Box identifies novel compounds with profound activities against Neospora caninum

Journal

INTERNATIONAL JOURNAL FOR PARASITOLOGY
Volume 47, Issue 12, Pages 801-809

Publisher

ELSEVIER SCI LTD
DOI: 10.1016/j.ijpara.2017.06.002

Keywords

MMV Pathogen Box; Neospora caninum; Drug development; Mitochondrion; Transmission electron microscopy; Neosporosis mouse model; Real time PCR; Cerebral infection

Categories

Funding

  1. Swiss National Science Foundation [310030_165782]
  2. Swiss National Science Foundation (SNF) [310030_165782] Funding Source: Swiss National Science Foundation (SNF)

Ask authors/readers for more resources

Neospora caninum is a major cause of abortion in cattle and represents an important veterinary health problem of great economic significance. The Medicines for Malaria Venture (MMV) Pathogen Box, an open-source collection of 400 compounds with proven anti-infective properties against a wide range of pathogens, was screened against a N. caninum beta-galactosidase reporter strain grown in human foreskin fibroblasts. A primary screening carried out at 1 mu M yielded 40 compounds that were effective against N. caninum tachyzoites. However, 30 of these compounds also affected the viability of the host cells. The 10 remaining compounds exhibited IC50 values between 4 and 43 nM. Three compounds with IC50 values below 10 nM, namely MMV676602, MMV688762 and MMV671636, were further characterized in vitro in more detail with respect to inhibition of invasion versus intracellular proliferation, and only MMV671636 had an impact on intracellular proliferation of tachyzoites. This was confirmed by transmission electron microscopy, showing that the primary target of MMV671636 was the mitochondrion. MMV671636 treatment of experimentally infected mice significantly reduced the number of animals with lung and brain infection, and these mice also exhibited a significantly reduced titer of antibodies directed against N. caninum antigens. Thus, MMV671636 is a promising starting point for the development of a future neosporosis therapy. (C) 2017 Australian Society for Parasitology. Published by Elsevier Ltd. All rights reserved.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available